Stanniocalcin 1 is overexpressed in multipotent mesenchymal stromal cells from acute myeloid leukemia patients.

Autor:	Schelker RC; Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg, Germany., Kratzer A; Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg, Germany., Müller G; Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg, Germany., Brochhausen C; Institute of Pathology, University of Regensburg, Regensburg, Germany., Hart C; Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg, Germany., Stempfl T; Center of Excellence for Fluorescent Bioanalytics (KFB), University of Regensburg, Regensburg, Germany., Heudobler D; Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg, Germany., Moehle C; Center of Excellence for Fluorescent Bioanalytics (KFB), University of Regensburg, Regensburg, Germany., Herr W; Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg, Germany., Iberl S; Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg, Germany., Grassinger J; Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.; St. Elisabeth Hospital, Straubing, Germany.
Jazyk:	angličtina
Zdroj:	Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 565-576.
DOI:	10.1080/16078454.2021.1962048
Abstrakt:	Objectives: Multipotent mesenchymal stromal cells (MSC) play a pivotal role in the bone marrow (BM) niche. Stanniocalcin 1 (STC1) secreted by MSC has been demonstrated to promote the survival of neoplastic cells and was suggested a marker for minimal residual disease of acute myeloid leukemia (AML). Therefore, we evaluated the expression of STC1 in MSC from AML patients (MSC AML ) compared to MSC from healthy donors (MSC HD ). Methods: Liquid culture assays of MSC AML and MSC HD were performed to compare expansion capacity. Gene expression profiles of MSC AML vs. MSC HD were established. Secretion of STC1 was tested by ELISA in MSC AML vs. MSC HD and expression of STC1 in AML- vs. HD-BM by immunohistochemistry. In addition, co-cultures of AML cells on MSC were initiated and ultrastructural intercellular communication patterns were investigated. Finally, the effect of blocking STC1 on AML cells was evaluated. Results: MSC AML showed significant decreased expansion capacity compared to MSC HD . Gene analysis revealed marked overexpression of STC1 in MSC AML . ELISA and immunohistochemical findings confirmed this observation. Electron microscopy analysis showed reciprocal stimulation between AML cells and MSC. Blockade of STC1 did not significantly affect AML cell proliferation and apoptosis. Discussion: Characteristics of MSC differ depending on whether they originate from AML patients or from HD. STC1 was mostly overexpressed in MSC AML compared to MSC HD . In vitro blockade of STC1, however, was not associated with AML cell proliferation and apoptosis. Conclusion: Differences in expression levels of glycoproteins from MSC AML compared to MSC HD not necessarily assume that these molecules are niche-relevant in leukemic disease.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF